Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Clinical trial NCT05008055 · COMPLETED
Trial details
- NCT number
- NCT05008055
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-03
- Primary completion
- 2023-08-22
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.